315 related articles for article (PubMed ID: 18939484)
21. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers.
Mishra N; Goyal AK; Tiwari S; Paliwal R; Paliwal SR; Vaidya B; Mangal S; Gupta M; Dube D; Mehta A; Vyas SP
Expert Opin Ther Pat; 2010 May; 20(5):661-79. PubMed ID: 20345332
[TBL] [Abstract][Full Text] [Related]
22. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.
Mestecky J; Michalek SM; Moldoveanu Z; Russell MW
Behring Inst Mitt; 1997 Feb; (98):33-43. PubMed ID: 9382757
[TBL] [Abstract][Full Text] [Related]
23. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases.
Tlaskalová-Hogenová H; Stepánková R; Hudcovic T; Tucková L; Cukrowska B; Lodinová-Zádníková R; Kozáková H; Rossmann P; Bártová J; Sokol D; Funda DP; Borovská D; Reháková Z; Sinkora J; Hofman J; Drastich P; Kokesová A
Immunol Lett; 2004 May; 93(2-3):97-108. PubMed ID: 15158604
[TBL] [Abstract][Full Text] [Related]
24. Nanotechnology solutions for mucosal immunization.
Chadwick S; Kriegel C; Amiji M
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):394-407. PubMed ID: 19931581
[TBL] [Abstract][Full Text] [Related]
25. Oral vaccine delivery: can it protect against non-mucosal pathogens?
Wang L; Coppel RL
Expert Rev Vaccines; 2008 Aug; 7(6):729-38. PubMed ID: 18665772
[TBL] [Abstract][Full Text] [Related]
26. [Mucosal vaccine: the powerful weapon for the host defense].
Takahashi I
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():632-6. PubMed ID: 17455694
[No Abstract] [Full Text] [Related]
27. Needle-free vaccine delivery.
Giudice EL; Campbell JD
Adv Drug Deliv Rev; 2006 Apr; 58(1):68-89. PubMed ID: 16564111
[TBL] [Abstract][Full Text] [Related]
28. Mucosal Vaccine Development Based on Liposome Technology.
Bernasconi V; Norling K; Bally M; Höök F; Lycke NY
J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567
[TBL] [Abstract][Full Text] [Related]
29. The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.
Dougan G; Ghaem-Maghami M; Pickard D; Frankel G; Douce G; Clare S; Dunstan S; Simmons C
Philos Trans R Soc Lond B Biol Sci; 2000 May; 355(1397):705-12. PubMed ID: 10874742
[TBL] [Abstract][Full Text] [Related]
30. Novel strategies using DNA for the induction of mucosal immunity.
McCluskie MJ; Davis HL
Crit Rev Immunol; 1999; 19(4):303-29. PubMed ID: 10530431
[TBL] [Abstract][Full Text] [Related]
31. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
[TBL] [Abstract][Full Text] [Related]
32. The postnatal development of the mucosal immune system and mucosal tolerance in domestic animals.
Bailey M; Haverson K
Vet Res; 2006; 37(3):443-53. PubMed ID: 16611557
[TBL] [Abstract][Full Text] [Related]
33. Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier.
Buddenborg C; Daudel D; Liebrecht S; Greune L; Humberg V; Schmidt MA
Int J Med Microbiol; 2008 Jan; 298(1-2):105-14. PubMed ID: 17936683
[TBL] [Abstract][Full Text] [Related]
34. Progress towards an AIDS mucosal vaccine: an overview.
Yuki Y; Nochi T; Kiyono H
Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S35-44. PubMed ID: 17652028
[TBL] [Abstract][Full Text] [Related]
35. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
Cox E; Verdonck F; Vanrompay D; Goddeeris B
Vet Res; 2006; 37(3):511-39. PubMed ID: 16611561
[TBL] [Abstract][Full Text] [Related]
36. [New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].
Denis F; Alain S; Ploy MC
Med Sci (Paris); 2007 Apr; 23(4):379-85. PubMed ID: 17433227
[TBL] [Abstract][Full Text] [Related]
37. [Mucosal immunity with implications for use in developing a new generation of vaccines].
Osek J; Truszczyński M
Postepy Hig Med Dosw; 1995; 49(4):469-86. PubMed ID: 8657643
[TBL] [Abstract][Full Text] [Related]
38. Recent progress in mucosal vaccine development: potential and limitations.
Lycke N
Nat Rev Immunol; 2012 Jul; 12(8):592-605. PubMed ID: 22828912
[TBL] [Abstract][Full Text] [Related]
39. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
Campo JD; Zayas C; Romeu B; Acevedo R; González E; Bracho G; Cuello M; Cabrera O; Balboa J; Lastre M
Methods; 2009 Dec; 49(4):301-8. PubMed ID: 19410000
[TBL] [Abstract][Full Text] [Related]
40. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Nomura T; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Oct; 30(29):5869-76. PubMed ID: 19646748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
